List view / Grid view
1 October 2013 | By Johnson & Johnson
“Everyone needs a complete eye exam because that’s how you are more likely to prevent blindness and eye disease..."
27 September 2013 | By Johnson & Johnson
Japan is the first country in the world where SOVRIAD™ is approved...
19 August 2013 | By Johnson & Johnson
Late-stage prostate cancer treatment strengthens oncology pipeline..
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
17 June 2013 | By Johnson & Johnson
Late-stage prostate cancer treatment strengthens oncology pipeline...
19 April 2013 | By Johnson & Johnson
Janssen will receive $11.25 per ADS which will result in an after-tax gain of approximately $213m...
31 December 2012 | By Johnson & Johnson
FDA has granted accelerated approval to SIRTURO™ Tablets for the treatment of pulmonary multi-drug resistant tuberculosis...
30 November 2012 | By Johnson & Johnson
Bill Weldon to step down after 41-year career at Johnson & Johnson...
19 September 2012 | By Bristol-Myers Squibb
New non-profit organization to speed pharmaceutical R&D...
8 December 2011 | By Johnson & Johnson
Compound in development for multiple B-cell hematologic malignancies...
21 October 2011 | By Johnson and Johnson
New data presented at EADV...
29 August 2011 | By Janssen Pharmaceuticals, Inc.
NUCYNTA® ER approved for the management of moderate to severe chronic pain...
16 June 2011 | By The Scott Partnership
Greenphire, partners with Mytrus to deliver novel and efficient web-based solutions for clinical trial patients...
4 June 2011 | By Johnson & Johnson
This study represents the first randomized, double-blind, placebo controlled Phase III trial to evaluate CTCs as a potential biomarker for overall survival...
28 April 2011 | By Johnson & Johnson
Johnson & Johnson and Synthes announce definitive merger agreement to create world’s most comprehensive orthopaedics business...
